
    
      Phase I - Two arms (Monotherapy and Combination therapy) with primary endpoints of Dose
      Limiting Toxicity Phase II - Two arms Monotherapy Cohort: Primary endpoint is Intracranial
      Objective Response Rate Combination Cohort: Primary endpoint is overall and extracranial
      Objective Response Rate among patients treated with the combination of tepotinib and
      concurrent TKI.
    
  